A Phase 1, open-label, multi-center, dose escalation and expansion study to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity of the WEE1 inhibitor IMP7068 monotherapy in patients with advanced solid tumors November 7, 2023